Brief: Shenzhen Hepalink Pharmaceutical to invest in Canada's Resverlogix Corp
Oct 13 (Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd
002399.SZ
* Says it plans to invest up to C$87 million ($69.75
million) in Canada's Resverlogix Corp RVX.TO
Source text in Chinese: http://bit.ly/2i9ZrGw
Further company coverage: 002399.SZ
($1 = 1.2473 Canadian dollars)
(Reporting by Hong Kong newsroom)
((hongkong.newsroom@thomsonreuters.com; (852) 2843-6441;
Reuters Messaging: chyenyee.lee.reuters.com@reuters.net))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA